Users Online: 1348

Home Print this page Email this page Small font sizeDefault font sizeIncrease font size

Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts | Login 

   Table of Contents      
Year : 2014  |  Volume : 4  |  Issue : 5  |  Page : 17-22

Effects on chrysin on lipid and xenobiotic metabolizing enzymes in l-NAME-induced hypertension

1 Department of Biochemistry, Rajah Serfoji Government College, Thanjavur, India
2 Department of Animal Science, Bharathidasan University, Tiruchirappalli, Tamil Nadu, India

Date of Web Publication19-Dec-2014

Correspondence Address:
Thekkumalai Malarvili
Department of Biochemistry, Rajah Serfoji Government College, Thanjavur - 613 001, Tamil Nadu
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/2231-0738.147459

Clinical trial registration ijnpnd_56_14R1_Ref

Rights and Permissions

Objective: Nω-nitro-l-arginine methyl ester (l-NAME) is a non-specific nitric oxide (NO) synthase inhibitor, commonly used for the induction of NO-deficient hypertension. Hypertension is a significant risk factor in cardiovascular complications. Materials and Methods: This study was undertaken to investigate the effects of chrysin on lipid metabolizing enzymes, xenobiotic metabolizing enzymes, and microalbuminuria and N-acetyl-β-d-glucosaminidase (NAG) in urine in l-NAME-induced hypertensive rats. Hypertension was induced in adult male Wistar rats weighing 180-220 g by oral administration of l-NAME (40 mg/kg BW) in drinking water for 4 weeks. Rats were treated with chrysin (25 mg/kg BW) for 4 weeks. Results: The activity of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase increased significantly in the liver and kidney, whereas the activities of lipoprotein lipase and lecithin cholesterol acyl transferase decreased significantly in the plasma of hypertensive rats. Conclusions: The xenobiotic phase I enzymes, microalbuminuria, and NAG significantly increased, whereas xenobiotic phase II enzymes decreased in l-NAME-treated rats. Oral administration of chrysin reduced hyperlipidemia-related risk of hypertension.

Keywords: 3-hydroxy-3-methylglutaryl coenzyme A, cytochrome P450, lecithin cholesterol acyl transferase, lipoprotein lipase, nitric oxide

How to cite this article:
Veerappan R, Malarvili T, Archunan G. Effects on chrysin on lipid and xenobiotic metabolizing enzymes in l-NAME-induced hypertension. Int J Nutr Pharmacol Neurol Dis 2014;4, Suppl S1:17-22

How to cite this URL:
Veerappan R, Malarvili T, Archunan G. Effects on chrysin on lipid and xenobiotic metabolizing enzymes in l-NAME-induced hypertension. Int J Nutr Pharmacol Neurol Dis [serial online] 2014 [cited 2021 Oct 26];4, Suppl S1:17-22. Available from:

   Introduction Top

Hypertension is a major public health problem and a leading cause of death and disability in developing countries. It remains a major risk factor in cardiovascular mortality and morbidity, through its effects on important target organs such as the heart, liver, and kidney. [1] It is mainly caused by endothelial dysfunction which is caused by nitric oxide (NO) deficiency. An inhibitor of nitric oxide synthase in vitro, Nω -nitro-l-arginine methyl ester (l-NAME), also inhibits the release of NO from endothelial cells and aortic rings. In vivo l-NAME supplementation to rodents is associated with the development of hypertension and a generalized decrease in peripheral blood flow, NO synthesis and release by endothelial cells play an important vascular relaxation effect, contributing to the modulation of vascular tone. [2] The obstruction of NO supplementation synthase by l-NAME seems to be involved in lipid metabolism alterations of increases in serum cholesterol levels in rats [3] and also affects the endothelium function in hypercholesterolemic rabbits, [4] through which it causes atherosclerosis. [5] So, the l-NAME-induced animal model is a well-consistent and commonly used model of investigations on hypertension. [6]

Besides their particular lipid-lowering effects, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) crank out a number of pleiotropic actions that have been recently studied in the area of cardiovascular and renal protection. Microalbuminuria is a significant indicator of the early stage of hypertensive nephropathy. Moreover, it is an important intermediary end-point which correlates strongly with advanced renal disease. [7] N-acetyl-β-d-glucosaminidase (NAG) is a lysosomal enzyme that is present in high concentrations in the renal proximal tubular cells. Urinary NAG excretion has been recommended as one of the useful marker for detection of changes in proximal tubular function long before elevation in other markers as proteinuria and rise in serum creatinine. [8] Elevated urinary NAG excretion has been reported as a cause of renal damage in hypertension. [9] Many clinical and experimental studies have demonstrated a relation between urinary NAG excretion and renal oxidative damage. [10]

Flavonoids are plant polyphenolic compounds that consist of a number of classes, such as flavonols, flavones, and flavans. Chrysin (5,7-dihydroxy flavone, structure shown in [Figure 1]) is a naturally occurring flavone present in flowers such as blue passion flower (Passiflora caerulea) and the Indian trumpet flower, as well as in edible items such as mushroom, [11] honey, and propolis. [12] Chrysin has been found to possess antioxidant, [13] anti-allergic, [14] anti-inflammatory, [15] anti-cancer, [16] antiestrogenic, [17] anxiolytic, [18] and antihypertensive [19],[20] properties. However, there are no scientific reports available on the effects of chrysin on l-NAME-induced hypertensive rats.
Figure 1: Chemical structure of chrysin (5,7 dihydroxyflavone)

Click here to view

The present study was aimed to study the effects of chrysin on urinary NAG and microalbuminuria levels, lipid metabolizing enzymes such as lecithin cholesterol acyl transferase (LCAT), lipoprotein lipase (LPL), and HMG-CoA reducatse, and hepatic xenobiotic metabolizing enzymes as markers in l-NAME-treated hypertensive rats.

   Materials and Methods Top


Chrysin and l-NAME was purchased from Sigma Chemical Co. (St Louis, MO, USA). All other chemicals used in this study were of analytical grade and obtained from E-Merck or HIMEDIA, Mumbai, India.


All the animal handling and experimental procedures were approved by the Institutional Animal Ethics Committee of Bharathidasan University (Registration no: 418/01/a/date 04.06.2001) and animals were cared for in accordance with the Indian National Law on Animal Care and Use. Male Wistar rats (180-220 g) were purchased from the Indian Institute of Science, Bangalore, India. They were housed in plastic cages with filter tops under controlled conditions of a 12-h light-dark cycle, 50% humidity, and a temperature of 28°C. All the rats received a standard pellet diet (Lipton Lever, Mumbai, India) and water ad libitum (BDU/IAEC63/2013).

Induction of l-NAME-induced arterial hypertension

l-NAME (40 mg/kg BW) was dissolved in drinking water and given to rats at an interval of 24 h for 8 weeks. The mean arterial blood pressure (MAP) was measured using tail cuff method. MAP measurements were performed at 1-8 weeks.

BP measurement

MAP was determined by the tail cuff method (Model 31; IITC, Woodland Hills, CA, USA). Each animal was introduced into a restrainer and kept quiet for 5 to 10 minutes. This procedure was repeated for 2-3 days in order to familiarize the rats with the restrainer. A rubber cuff (proximally) and a photoelectric sensor of pulsations (more distally) were placed around the tail. The sensor was connected to an amplifier and pulsations were recorded on a power lab-recording unit. Peaks and troughs in the blood pressure curve were detected. A large number of recordings were taken; each value recorded was derived from eight to ten consecutive measurements (within approximately 15 minutes), which were then averaged to give one value representative of each experimental condition.

The animals were placed in a heated chamber at an ambient temperature of 30-34°C for 15 min, and for each animal, BP values (1-9) were recorded. The lowest three readings were averaged to obtain a mean BP. All recordings and data analyses were done using a computerized data acquisition system and software.

Design of this study

Animals were divided into four groups of six rats each and all were fed the standard pellet diet. Grouping of rats is as given below.

  • Group I: Control
  • Group II: Control + chrysin (25 mg/kg of BW) after 4 th week
  • Group III: l-NAME-induced hypertension (40 mg/kg of BW)
  • Group IV: l-NAME-induced hypertension + chrysin (25 mg/kg of BW).

Chrysin were administered orally once in a day in the morning for 4 weeks. The compound was suspended in 2% dimethyl sulfoxide vehicle solution and fed to animals by intubation. After 8 th week, the animals were sacrified by cervical dislocation. Blood was collected in clean dry test tubes and allowed to coagulate at an ambient temperature for 30 min. The serum was separated by centrifugation at 2000 rpm for 10 min. The blood, collected in a heparinized centrifuge tube, was centrifuged at 2000 rpm for 10 min and the plasma separated by aspiration was used for the estimations. The liver and kidney were immediately removed and washed in ice-cold saline to remove blood. The tissues were sliced and homogenized in 0.1 M Tris-HCl buffer (pH 7.0). The homogenates were centrifuged at 1000 rpm for 10 min at 0°C in a cold centrifuge.

Experimental methods

Estimation of lipid marker enzymes

The activities of HMG-CoA reductase in liver and kidney, plasma LPL, and plasma LCAT were assayed by the method of Rao and Ramakrishnan, [21] Korn, [22] and Hitz et al., [23] respectively. Control tubes containing only the substrate were treated similarly to check for complete inactivation of plasma during substrate preparations. LCAT activity was expressed as a function of the disappearance of free cholesterol during the incubation period.

Cytochrome P450 (CYP) and cytochrome b5 were assayed by the method of Omura and Sato. [24] NADPH-cytochrome P450 reductase (EC was assayed by the method of Omura and Takesue. [25] Cytochrome P4502E1 (CYP4502E1) activity was assayed by the method of Watt et al. [26] NADH-cytochrome b5 reductase (EC activity was assayed by the method of Mihara and Sato. [27] DT-diaphorase (EC activity was assayed by the method of Ernster et al. [28]

Urinary NAG level was measured according to the method of Yakata et al., [29] at 580 nm as 3-cersol sulfonphthalein released from 3-cresol sulfonphthaleinyl β-d-glucosaminide. Creatinine level in urine was measured using standard spectrophotometric methods (autoanalyzer, Abbott Aeroset; Abbott Diagnostics, IL, USA). Quantitative determination of albumin in the urine was performed using competitive chemiluminescent enzyme immunoassay using kits (Immulite 2000 Albumin) and Immulite Analyzer (DPC, Los Angeles, CA, USA). Urinary NAG excretion was expressed as U/g urinary creatinine to rule out the influence of urinary dilution or concentration. In addition, the final value of microalbuminuria was represented by the ratio of albumin and creatinine in urine (l g/mg creatinine). NO in the plasma samples was measured based on Griess reaction. [30]

Statistical analysis

Data were analyzed by one-way analysis of variance followed by a Duncan's multiple range tests using a commercially available statistics software package (SPSS for Windows, version 11.0; SPSS Inc., Chicago, IL, USA). Results were presented as mean ± standard deviation (SD) values and P < 0.05 were regarded as statistically significant.

   Results Top

The activity of HMG-CoA reductase in control rats and l-NAME-induced hypertensive rats is shown in [Table 1]. Increased activity of HMG-CoA reductase was observed in the liver and kidney of l-NAME-treated hypertensive rats (group III). Treatment with chrysin (group IV) significantly (P < 0.05) decreased the activity of HMG-CoA reductase in these tissues when compared to l-NAME-treated hypertensive control rats (group III). The activities of LCAT and LPL of control rats and l-NAME-induced hypertensive rats are shown in [Table 2]. Decreased activities of LCAT and LPL were observed in the plasma of l-NAME-treated hypertensive rats (group III) as compared to control rats. Administration of chrysin (group IV) to hypertensive rats significantly (P < 0.05) increased the activities of LCAT and LPL when compared to hypertensive control rats (group III).
Table 1: Effect of chrysin on the activities of HMG-CoA reducatse in liver and kidney

Click here to view
Table 2: Effect of chrysin on the activities of LPL and LCAT in plasma

Click here to view

l-NAME (group III) treated rats showed increased activities of hepatic microsomal phase I enzymes, such as CYP, cytochrome b5, cytochrome P4502E1, NADPH-cytochrome P450 reductase, and NADH-cytochrome b5 reductase, as compared to the control rats (group I). Chrysin supplementation to l-NAME (group IV) treated rats reduced the activities of all the above phase I enzymes in the liver as compared to l-NAME alone (group III) treated rats [Table 3]. The activities of the liver cytosolic phase II enzymes such as DT-diaphorase showed decreased activities in the l-NAME (group III) treated rats as compared to the controls. Chrysin supplementation to l-NAME rats (group IV) increased the activities of DT-diaphorase as compared to the l-NAME alone (group III) treated rats [Table 3].
Table 3: Effect of chrysin on hepatic xenobiotic metabolizing enzymes of control and experimental rats

Click here to view

[Table 4] shows that the level of urinary NAG or microalbumin excretion increased and plasma NOx decreased in l-NAME-administered rats (group III) compared to the control group (group I) (P < 0.05). Interestingly, in rats administered l-NAME plus chrysin (group IV), the urinary NAG or microalbumin excretion was significantly (P < 0.05) reduced and increased plasma NOx was found, compared with the l-NAME alone treated rats (group III).
Table 4: Effect of chrysin on urinary microalbuminuria, urinary NAG/Cr, and NOx plasma

Click here to view

   Discussion Top

HMG-CoA reductase has an important function in the regulation of cholesterol metabolism and it is a rate-limiting enzyme in the pathway of cholesterol biosynthesis. The present study shows a significant increase in the activity of HMG-CoA reductase in the liver and kidney of l-NAME-induced hypertensive rats. The enhanced activity of HMG-CoA reductase might be due to increased lipid peroxidation in l-NAME-treated rats in our study. An increase in HMG-CoA reductase activity leads to excessive production and accumulation of cholesterol, resulting in the formation of foam cells, a prerequisite step in the development of atherosclerosis caused by NO deficiency. [31] Supplementation of chrysin controlled the activity of HMG-CoA reductase in l-NAME-treated rats. This might be due to the inhibition of lipid peroxidation.

Liver is the major organ of LCAT synthesis. LCAT is an enzyme bound to high-density lipoproteins (HDLs) and low-density lipoproteins (LDLs) in the plasma. LCAT catalyzes the formation of cholesterol esters in lipoproteins. Decreased HDL-cholesterol (HDL-C) may be due to diminished LCAT activity and it contributes to increased cholesterol levels. An interesting observation was that chrysin significantly decreased the activity of LPL and LCAT in l-NAME-induced hypertensive rats. This shows the antilipidemic effect of chrysin in l-NAME-treated rats.

Phase I detoxification enzymes, CYP, comprise a multigene superfamily of microsomal heme-thiolate proteins that play critical roles in endogenous as well as xenobiotic metabolism and their detoxification. [32] The elevated activities of cytochrome P450 enzymes both in the liver and extra hepatic tissues can result in extremely low bioavailability of a number of orally administered phytochemicals. [33] In the present study, an increased activity of the cytochrome P450 family enzymes was observed in the liver of l-NAME-treated rats which was reversed on supplementation with chrysin. This strategic inhibition of P450 enzymes could be used to improve bioavailability of highly metabolized drugs. Chrysin is known to inhibit CYP1A activity, resulting in the modulation of drug metabolizing enzymes and regulation of cellular oxidation process. Phase II enzyme such as DT-diaphorase help in conjugating the xenobiotics to endogenous ligands like glutathione (GSH), glucuronic acid, acetic acid, or sulfuric acids, thus enhancing their solubility and excretion. Generally, inhibition of phase 1 enzymes concomitantly with induction of phase II enzymes is considered a logical strategy in chemoprevention. [34] l-NAME-treated rats showed decreased activities of the phase II enzymes. Supplementation with chrysin enhanced the phase II enzymes' activities, thereby helping in the regulation of xenobiotic metabolism.

In hypertensive patients, high urinary NAG and microalbumin excretion might reflect lysosomal dysfunction of both glomerular and proximal tubular epithelial cells. [35] In the present study, increased urinary NAG and microalbumin excretion was observed in hypertensive rats. This significant increase of the excretion of urinary NAG and microalbuminuria accounts for the occurrence of tubular cell damage due to oxidative stress in hypertensive rats. Increased peroxynitrite levels have been reported in the proximal tubules of patients with hypertensive nephropathy. Peroxynitrite generated in the tubular epithelium during renal hypertension has a potential to impair the structure of tubular cells. [36] By interfering with peroxynitrite-related pathways, chrysin proved to be effective in the prevention of hypertension and oxidative tubular renal injury. Furthermore, long-term chrysin administration resulted in decline in urinary NAG and microalbumin excretion. Also, we found a positive correlation among those parameters. These findings showed that chrysin may have beneficial effects in preventing tubular damage in hypertensive rat kidney.

NO synthesis and release by endothelial cells plays an important vascular relaxation effect, [37] contributing to the modulation of vascular tone. In addition, NO has been identified as important in other cellular events, such as vascular smooth muscle cell proliferation. [38] NO, synthesized by endothelial NO synthase (eNOS), is a major regulator of the vascular tone. Arterial hypertension, an important risk factor of cardiovascular diseases, is characterized by the production of excessive reactive oxygen species interacting with NO and reducing its bioavailability; oxidation of NO to peroxynitrite by reactive oxygen species induces oxidative stress. [39] Bioavailability of NO can be maintained by inhibition of oxidative stress, and therefore the agents with antioxidant properties inactivating free radicals increase NO bioavailability and can improve regulation of the vascular tone. Our findings also confirmed that chrysin-treated l-NAME groups significantly increased the NO level in plasma. These findings most likely reflect the diminished vasodilator action of endogenous NO, where l-NAME may have interfered with the activity of eNOS. [40] Administration of chrysin protects against renal and hepatic damage.

   Conclusion Top

In conclusion, inhibition of NO synthase by chrysin has been shown to protect kidney and liver against oxidative damage induced by hypertension. Chrysin supplementation ameliorates the biochemical changes in the liver and kidney. Chrysin at 25 mg/kg BW offered marked renal and hepatoprotection by reversing the changes and exbited its protective role in reducing hyperlipidemia in l-NAME-induced hypertensive rats.

   References Top

Saravanakumar M, Raja B. Protective effect of borneol in liver and kidney tissues in l-NAME induced hypertensive rats; a FTIR report; oral presentation. Int J Nutr Pharmacol Neurol Dis 2011;1:19-26.  Back to cited text no. 1
Moncada S, Palmer RM, Higgs EA. Nitric oxide: Physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991;43:109-42.  Back to cited text no. 2
Khedara A, Kawai Y, Kayashita K, Kato N. Feeding rats the nitric oxide synthase inhibitor, L-N (omega) nitroarginine, elevates serum triglyceride and cholesterol and lowers hepatic fatty acid oxidation. J Nutr 1996;126:2563-7.  Back to cited text no. 3
Cayatte AJ, Palacino JJ, Horten K, Cohen RA. Chronic inhibition of nitric oxide production accelerates neointima formation and impairs endothelial function in hypercholesterolemic rabbits. Arterioscler Thromb 1994;14:753-9.  Back to cited text no. 4
Naruse K, Shimizu K, Muramatsu M, Toki Y, Miyazaki Y, Okumura K, et al. Long-term inhibition of NO synthesis promotes atherosclerosis in the hypercholesterolemic rabbit thoracic aorta. PGH2 does not contribute to impaired endothelium-dependent relaxation. Arterioscler Thromb 1994;14:746-52.  Back to cited text no. 5
Toba H, Nakagawa Y, Miki S, Shimizu T, Yoshimura A, Inoue R, et al. Calcium channel blockades exhibit anti-inflammatory and antioxidative effects by augmentation of endothelial nitric oxide synthase and the inhibition of angiotensin converting enzyme in the N (G)-nitro-L-arginine methyl ester-induced hypertensive eat aorta: Vasoprotective effects beyond the blood pressure-lowering effects of amlodipine and manidipine. Hypertens Res 2005;28:689-700.  Back to cited text no. 6
Dinçer Y, Telci A, Kayali R, Yilmaz IA, Cakatay U, Akçay T. Effect of alpha-lipoic acid on lipid peroxidation and anti-oxidant enzyme activities in diabetic rats. Clin Exp Pharmacol Physiol 2002;29:281-4.  Back to cited text no. 7
Bosomworth MP, Aparicio SR, Hay AW. Urine N-acetyl-beta-D-glucosaminidase-a marker of tubular damage? Nephrol Dial Transplant 1999;14:620-6.  Back to cited text no. 8
Pere AK, Lindgren L, Tuomainen P, Krogerus L, Rauhala P, Laakso J, et al. Dietary potassium and magnesium supplementation in cyclosporine-induced hypertension and nephrotoxicity. Kidney Int 2000;58:2462-72.  Back to cited text no. 9
Oktem F, Ozguner F, Yilmaz HR, Uz E, Dündar B. Melatonin reduces urinary excretion of N-acetyl-beta-D-glucosaminidase, albumin and renal oxidative markers in diabetic rats. Clin Exp Pharmacol Physiol 2006;33:95-101.  Back to cited text no. 10
Jayakumar T, Thomas PA, Geraldine P. In-vitro antioxidant activities of an ethanolic extract of the oyster mushroom, Pleurotus ostreatus. Innov Food Sci Emerg Technol 2009;10:228-34.  Back to cited text no. 11
Williams CA, Harborne JB, Newman M, Greenham J, Eagles J. Chrysin and other leaf exudate flavanoids in the genus Pelargonium. Phytochemistry 1997;46:1349-53.  Back to cited text no. 12
Malarvili T, Veerappan R. Effects of chrysin on free radicals and enzymic antioxidants in Nω-nitro-l-arginine methyl ester: Induced hypertensive rats. Int J Nutr Pharmacol Neurol Dis 2014;4:112-7.  Back to cited text no. 13
  Medknow Journal  
Pearce FL, Befus AD, Bienenstock J. Mucosal mast cells. III. Effect of quercetin and other flavonoids on antigen-induced histamine secretion from rat intestinal mast cells. J Allergy Clin Immunol 1984;73:819-23.  Back to cited text no. 14
Fishkin RJ, Winslow JT. Red wine, white wine, rosé wine, and grape juice inhibit angiotensin-converting enzyme in human endothelial cells. Int J Nutr Pharmacol Neurol Dis 2013;3:17-23.  Back to cited text no. 15
Karthikeyan S, Srinivasan R, Wani SA, Manoharan S. Chemopreventive potential of chrysin in 7, 12-dimethylbenz (a) anthracene-induced hamster buccal pouch carcinogenesis. Int J Nutr Pharmacol Neurol Dis 2013;3:46-53.  Back to cited text no. 16
  Medknow Journal  
Kao YC, Zhou C, Sherman M, Laughton CA, Chen S. Molecular basis of the inhibition of human aromatase (estrogen synthetase) by flavone and isoflavone phytoestrogens: A site-directed mutagenesis study. Environ Health Perspect 1998;106:85-92.  Back to cited text no. 17
Wolfman C, Viola H, Paladini A, Dajas F, Medina JH. Possible anxiolytic effects of chrysin, a central benzodiazepine receptor ligand isolated from Passiflora coerulea. Pharmacol Biochem Behav 1994;47:1-4.  Back to cited text no. 18
Ramanathan V, Thekkumalai M. Role of chrysin on hepatic and renal activities of Nω-nitro-l-arginine-methylester induced hypertensive rats. Int J Nutr Pharmacol Neurol Dis 2014;4:58-63.  Back to cited text no. 19
  Medknow Journal  
Villar IC, Jiménez R, Galisteo M, Garcia-Saura MF, Zarzuelo A, Duarte J. Effects of chronic chrysin treatment in spontaneously hypertensive rats. Planta Med 2002;68:847-50.  Back to cited text no. 20
Rao AV, Ramakrishnan S. Indirect assessment of hydroxymethylglutaryl-CoA reductase (NADPH) activity in liver tissue. Clin Chem 1975;21:1523-5.  Back to cited text no. 21
Korn ED. Clearing factor, a heparin-activated lipoprotein lipase. I. Isolation and characterization of the enzyme from normal rat heart. J Biol Chem 1955;215:1-14.  Back to cited text no. 22
Hitz J, Steinmetz G, Siest G. Plasma lecithin: Cholesterol acyltransferase - reference values and effects of xenobiotics. Clin Chim Acta 1983;133:85-96.  Back to cited text no. 23
Omura T, Sato R. The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 1964;239:2370-8.  Back to cited text no. 24
Omura T, Takasue S. A new method for simultaneous purification of cytochrome b5 and NADPH-cytochrome c reductase from rat liver microsomes. J Biochem 1970;67:249-57.  Back to cited text no. 25
Watt KC, Plopper CG, Buckpitt AR. Measurement of cytochrome P450 2E1 activity in rat tracheobronchial airways using high-performance liquid chromatography with electrochemical detection. Anal Biochem 1997;248:26-30.  Back to cited text no. 26
Mihara K, Sato R. Partial purification of NADH-cytochrome b 5 reductase from rabbit liver microsomes with detergents and its properties. J Biochem 1972;71:725-35.  Back to cited text no. 27
Ernster L, Danielson L, Ljunggren M. DT diaphorase. I. Purification from the soluble fraction of rat-liver cytoplasm, and properties. Biochem Biophys Acta 1979;58:171-88.  Back to cited text no. 28
Yakata M, Sugita O, Sakai T, Uchiyama K, Wada K. Urinary enzyme determination and its clinical significance. C. Enzyme derived from the kidney tubular epithelium-N-acetyl-beta-D-glucosaminidase. 4. Preclinical evaluation of the urinary NAG activity and changes in renal diseases. Rinsho Byori 1983;Spec No 56:90-101.  Back to cited text no. 29
Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS, Tannenbaum SR. Analysis of nitrate, nitrite, and [15N] nitrate in biological fluids. Anal Biochem 1982;126:131-8.  Back to cited text no. 30
Esterbauer H, Gebicki J, Puhl H, Jürgens G. The role of lipid peroxidation and antioxidants in the oxidative modification of LDL. Free Radic Biol Med 1992;13:341-90.  Back to cited text no. 31
Nebert DW, Russell DW. Clinical importance of the cytochromes P450. Lancet 2002;360:1155-62.  Back to cited text no. 32
Kitteringham NR, Pirmohamed M, Park BK. The pharmacology of the cytochrome P450 enzyme system. Bail Clin Anaesthesiol 1998;12:2.  Back to cited text no. 33
Gerhäuser C, Klimo K, Heiss E, Neumann I, Gamal-Eldeen A, Knauft J, et al. Mechanism-based in vitro screening of potential cancer chemopreventive agents. Mutat Res 2003;523-524:163-72.  Back to cited text no. 34
Zhang C, Imam SZ, Ali SF, Mayeux PR. Peroxynitrite and the regulation of Na(+), K(+)-ATPase activity by angiotensin II in the rat proximal tubule. Nitric Oxide 2002;7:30-5.  Back to cited text no. 35
Ruiz-Ortega M, Ortiz A. Angiotensin II and reactive oxygen species. Antioxid Redox Signal 2005;7:1258-60.  Back to cited text no. 36
Mori Y, Ohyanagi M, Koida S, Ueda A, Ishiko K, Iwasaki T. Effects of endothelium-derived hyperpolarizing factor and nitric oxide on endothelial function in femoral resistance arteries of spontaneously hypertensive rats. Hypertens Res 2006;29:187-95.  Back to cited text no. 37
Paulis L, Zicha J, Kunes J, Hojna S, Behuliak M, Celec P, et al. Regression of L-NAME-induced hypertension: The role of NO-pathway and endothelium-derived constricting factor. Hypertens Res 2008;31:793-803.  Back to cited text no. 38
De Gennaro Colonna V, Rigamonti A, Fioretti S, Bonomo S, Manfredi B, Ferrario P, et al. Angiotensin-converting enzyme inhibition and angiotensin AT1-receptor antagonism equally improve endothelial vasodilator function in L-NAME-induced hypertensive rats. Eur J Pharmacol 2005;516:253-9.  Back to cited text no. 39
Kumar S, Saravana Kumar M, Raja B. Efficacy of piperine, an alkaloidal constituent of pepper on nitric oxide, antioxidants and lipid peroxidation markers in L-NAME induced hypertensive rats. Int J Res Pharm Sci 2010;1:300-7.  Back to cited text no. 40


  [Figure 1]

  [Table 1], [Table 2], [Table 3], [Table 4]

This article has been cited by
1 Chrysin Pretreatment Improves Angiotensin System, cGMP Concentration in L-NAME Induced Hypertensive Rats
Ramanathan Veerappan,Thekkumalai Malarvili
Indian Journal of Clinical Biochemistry. 2018;
[Pubmed] | [DOI]
2 Modulatory Effect of Achyranthes aspera L., Seeds on Carbohydrates and Protein Bound Enzymes on High Fructose Fed Diet
Veerappan Ramanathan,Malarvili Thekkumala
Journal of Pharmacology and Toxicology. 2017; 12(3): 154
[Pubmed] | [DOI]
3 Chrysin Ameliorates the Lipid Profiles in N?-nitro-l-arginine-methylester-induced Hypertensive Rats
Veerappan Ramanathan,Senthilkumar Rajagopal
American Journal of Biochemistry and Molecular Biology. 2016; 6(2): 60
[Pubmed] | [DOI]


    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

  In this article
    Materials and Me...
    Article Figures
    Article Tables

 Article Access Statistics
    PDF Downloaded87    
    Comments [Add]    
    Cited by others 3    

Recommend this journal